Low Merlin expression and high Survivin labeling index are indicators for poor prognosis in patients with malignant pleural mesothelioma

Alterations of the tumor suppressor Neurofibromatosis type II (NF2) have been reported in about 40% of Malignant pleural mesothelioma (MPM) patients. NF2 (Merlin) deficiency leads to alterations of the Hippo pathway; resulting in activation of the oncogenic Yes Associated Protein-1 (YAP1). Our aim was to investigate the association between these alterations and clinical outcomes.

Source: Molecular Oncology - June 24, 2016 Category: Cancer & Oncology Authors: Mayura Meerang, Karima B érard, Martina Friess, Byron K.Y. Bitanihirwe, Alex Soltermann, Bart Vrugt, Emanuela Felley-Bosco, Raphael Bueno, William G. Richards, Burkhardt Seifert, Rolf Stahel, Walter Weder, Isabelle Opitz Source Type: research